#RGT-61159
LightNews LightNews
newsen.bsky.social
Rgenta Therapeutics Unveils Promising Data on RGT-61159 Inhibitor at EHA 2025 Congress#USA#Rgenta_Therapeutics#Woburn#RGT-61159#MYB_RNA
Rgenta Therapeutics Unveils Promising Data on RGT-61159 Inhibitor at EHA 2025 Congress
Rgenta Therapeutics will present preclinical findings on its innovative MYB RNA inhibitor, RGT-61159, at EHA 2025 in Milan, showcasing significant anti-tumor activity.
third-news.com
May 14, 2025 at 2:34 PM
newsen.bsky.social
Innovative Oral Small Molecule RGT-61159 Shows Promise Against AML#USA#AML#Rgenta_Therapeutics#RGT-61159#Woburn,_MA
Innovative Oral Small Molecule RGT-61159 Shows Promise Against AML
Rgenta Therapeutics has unveiled preclinical data indicating that their oral MYB inhibitor, RGT-61159, exhibits strong anti-tumor effects in AML models and synergizes effectively with standard treatments.
third-news.com
April 25, 2025 at 5:11 PM
newsen.bsky.social
Rgenta Therapeutics Showcases Promising Anti-Cancer Drug RGT-61159 at ASH Annual Meeting#United_States#San_Diego#AML#Rgenta_Therapeutics#RGT-61159
Rgenta Therapeutics Showcases Promising Anti-Cancer Drug RGT-61159 at ASH Annual Meeting
Rgenta Therapeutics presents groundbreaking preclinical data on RGT-61159, a novel MYB inhibitor, at the ASH Annual Meeting, promising new avenues for AML treatment.
third-news.com
December 9, 2024 at 5:08 PM
renesugar.bsky.social
eg.

Erlotinib ( #FOXA2; EGFR-TKIs)
RGT-61159 ( #MYB) www.rgentatx.com/clinical-tri...
Romidepsin ( #HDACi; #HDAC2)
Clinical Trials for RGT-61159 | Rgenta Therapeutics Inc. | Boston, MA
Join Rgenta's Phase 1a/b trial for RGT-61159, targeting advanced cancers. Contact us to learn about innovative treatment options.
www.rgentatx.com
July 26, 2025 at 2:14 PM
renesugar.bsky.social
RGT-61159 ( #MYB)

www.rgentatx.com/clinical-tri...

Study of Safety and Efficacy of RGT-61159 in Adults with Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

clinicaltrials.gov/study/NCT064...
Clinical Trials for RGT-61159 | Rgenta Therapeutics Inc. | Boston, MA
Join Rgenta's Phase 1a/b trial for RGT-61159, targeting advanced cancers. Contact us to learn about innovative treatment options.
www.rgentatx.com
July 26, 2025 at 2:14 PM
l2plabs.bsky.social
Rgenta Therapeutics Presents Preclinical Data on RGT-61159, a Potent, Selective Oral Small Molecule Inhibitor of MYB, Demonstrating Robust Anti-Tumor Activity in Several Monotherapy Models of AML and Synergistic Activity when Combined with Standard of Care for AML
Data highlight the potential of RGT-61159 to treat a broad acute myeloid leukemia (AML) patient population as a single agent and combination benefit with Standard of Care Data are being presented at the American Association for Cancer Research (AACR) 2025 Annual Meeting WOBURN, Mass.,...
dlvr.it
April 25, 2025 at 5:10 PM
drtimos.bsky.social
LucidQuest Views >>> Oncology Weekly News – September 22nd 2025 Comment below! #LucidQuest #PharmaCI
Oncology Weekly News – September 22nd 2025
Oncology Update: RGT-61159 Orphan Drug, CRB-701 Fast Track, PDS0101 Survival Data & More From FDA orphan drug and fast-track designations […] The post Oncology Weekly News – September 22nd 2025 appeared first on LucidQuest Ventures.
dlvr.it
September 22, 2025 at 8:20 AM